EGFR and non-small cell lung carcinoma: It has been suggested that STAT3 is extensively correlated with therapeutic resistance to EGFR-TKIs in NSCLC cells and that CsA augments the effect of Gef remarkably by inhibiting STAT3 activation.35 Therefore, we evaluated whether the CsA-NP-mediated sensitization to Gef is also dependent on STAT3 inhibition in PC-9, PC-9-GR, and H1975 cells by immunoblotting.